Stockscreener 앱 받기
1.24
2.36%
-0.03
Maxcyte Inc 주식(MXCT)의 최신 뉴스
MYE0 Forecast — Price Target — Prediction for 2027 - TradingView
MaxCyte, Inc. Actuals & Estimates (NASDAQ:MXCT) - TradingView
MXCT Forecast — Price Target — Prediction for 2027 - TradingView
MaxCyte Inc (MXCT) Institutional Confidence - TradingKey
VectorBuilder Partners With MaxCyte® to Advance Clinical-Grade Cell Engineering - Business Wire
Form 4 MaxCyte Inc For: 22 June By Investing.com - Investing.com South Africa
MaxCyte (MXCT) grants RSUs and stock options to director - Stock Titan
MaxCyte (MXCT) director awarded RSUs and stock options in annual grant - Stock Titan
MaxCyte (MXCT) director receives RSUs and options in annual equity grant - Stock Titan
MAXCYTE (NASDAQ: MXCT) director receives RSU and option grants as annual equity award - Stock Titan
MAXCYTE (MXCT) director Cynthia Collins receives RSUs and 49,579-share option grant - Stock Titan
MaxCyte (MXCT) director receives RSUs and 49,579 stock options in new grant - Stock Titan
MaxCyte (MXCT) director Patrick Balthrop receives RSU and stock option grants - Stock Titan
MaxCyte (MXCT) director receives RSU and stock option grant - Stock Titan
Craig-Hallum Reaffirms Their Buy Rating on MaxCyte (MXCT) - The Globe and Mail
MaxCyte Stockchart levels and volatility on a quiet news day - Ad-hoc-news.de
MaxCyte Inc (MXCT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
MaxCyte, Inc. (MXCT) Announces Results of Shareholder Vote and Audit Firm Ratification – June 17, 2026 - Minichart
MaxCyte shareholders elect directors and approve auditor at annual meeting - Investing.com
MaxCyte shareholders elect directors and approve auditor at annual meeting By Investing.com - Investing.com Nigeria
MaxCyte Inc (MXCT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
MaxCyte Inc (MXCT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
MaxCyte Shareholders Reelect Directors and Ratify Auditor - TipRanks
MaxCyte Inc (MXCT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
MaxCyte Inc (MXCT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
MaxCyte Inc (MXCT) Valuation: PE, PB & Fair Value Analysis - TradingKey
MaxCyte Inc (MXCT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
MaxCyte Inc (MXCT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
MaxCyte Regains Nasdaq Compliance After Bid Price Recovery - The Globe and Mail
MaxCyte (NASDAQ: MXCT) investors reelect board and ratify auditor - Stock Titan
MaxCyte regains compliance with Nasdaq minimum bid price rule By Investing.com - Investing.com Canada
MaxCyte regains compliance with Nasdaq minimum bid price rule - Investing.com
MaxCyte Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
MaxCyte (NASDAQ: MXCT) restores Nasdaq minimum bid-price compliance after warning - Stock Titan
MXCT Q1 2026 Earnings: EPS Surprises Strongly to the Upside, Beating Estimates by 50.98%Revenue Inflection Point - newsline.com
MaxCyte Inc. (MXCT) Posts 3.4% Gain, Testing Resistance at $1.27Entry Point Alerts - newsline.com
MaxCyte (MXCT) Edges Higher on Increased Activity, Tests Key Resistance at $1.27Stop Hunt - The Legal Advocate
MaxCyte Inc. (MXCT) Surges 9.7%: Testing Key Resistance at $1.25Breakout Stock Alerts - The Legal Advocate
MaxCyte Inc. (MXCT) Surges 7.87% as Shares Test Key Resistance LevelMomentum Surge Alerts - The Legal Advocate
MXCT Q1 2026 Earnings: EPS Beat Estimates by 50.98% Despite Negative EarningsDiluted EPS Report - The Legal Advocate
MaxCyte outlines $30M-$32M 2026 revenue outlook as board authorizes $10M share repurchase program - MSN
MaxCyte Inc. (MXCT) Struggles Near Support as Selling Pressure PersistsFree Signal Network - Newser
MaxCyte (MXCT) Q1 2026 Earnings: Narrower Loss Beats Estimates, Stock DeclinesSegment Revenue Breakdown - Newser
MaxCyte Inc stock (US57777K1060): cell-therapy enabler after recent earnings update - AD HOC NEWS
MaxCyte, Inc. (MXCT) reports Q1 loss, tops revenue estimates - MSN
MaxCyte Inc stock (US57777K1060): recent volatility and growth hopes in cell therapy tools - AD HOC NEWS
MaxCyte Q1 earnings call highlights - MSN
2.35%
0.70%
자본화:
|
볼륨(24시간):